FDA approved Pylarify TruVu, a higher-radioactivity-concentration formulation of piflufolastat F 18 designed to increase batch size and distribution efficiency while maintaining the established ...
SHERBET, an individual patient data post hoc pooled analysis of 5 prospective trials, compared HDR-BT with SBRT in patients with intermediate-risk prostate cancer.
Oxybutynin significantly reduced hot flash frequency and severity compared with placebo among men with prostate cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results